Paper Details

  1. Home
  2. Paper Details

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).

Author: AltenhoferJulia, BusyginaKristina, FolwacznyAlexander, HenzeKerstin, ParhoferKlaus G, WaldmannElisa, WuLiya

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Familial dysbetalipoproteinemia (FDBL) is a rare genetic disorder that disrupts the body's ability to process fats. People with FDBL have a higher chance of developing heart disease. This study investigates the potential benefits of PCSK9 inhibitors, a new type of medication, in managing FDBL.
Paper Details　
Original Abstract of the Article :
Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder characterized by the formation of abnormal triglyceride- and cholesterol-rich lipoproteins (remnant particles). Patients with FDBL have a high risk for atherosclerotic disease. The effect of PCSK9 inhibition on lipoproteins and i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942248/

データ提供：米国国立医学図書館（NLM）

Investigating the Effect of PCSK9 Inhibition on Familial Dysbetalipoproteinemia

Familial dysbetalipoproteinemia (FDBL), a rare genetic disorder characterized by abnormal lipid metabolism, can significantly increase the risk of heart disease. This study investigates the effect of PCSK9 inhibition, a promising new approach to lowering cholesterol levels, on lipoproteins and their subfractions in patients with FDBL.

A New Route in the Desert of Lipid Disorders

The study's findings offer a potential new treatment strategy for individuals with FDBL, providing a pathway through the challenging terrain of this rare lipid disorder.

Hope for a Healthier Future

The study's findings suggest that PCSK9 inhibition could be a valuable tool in managing FDBL and reducing the risk of cardiovascular complications. It is like finding a hidden spring in the desert, offering a refreshing source of hope for individuals with this disorder.

Dr. Camel's Conclusion

This study highlights the importance of research in finding innovative therapies for rare diseases. Just as a camel needs to adapt to its environment to survive, healthcare professionals need to be creative and resourceful in their search for effective treatments.

Date :
  1. Date Completed 2022-05-04
  2. Date Revised 2022-05-04
Further Info :

Pubmed ID

35320320

DOI: Digital Object Identifier

PMC8942248

Related Literature

Article Analysis
・Effective treatment of vldl cholesterol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.